This webcast features: Jessica Waller, PhD, Principal Scientist Biologics Development, Bristol Myers Squibb. Bispecific antibody configurations with multi-targeting capabilities are evolving as new generation biologic therapeutics with potential for enhanced efficacy and reduced toxicity. Significant challenges arise with downstream purification of these molecules due to a unique panel of product-related variants or mispaired species that must be monitored and cleared in product pools. Viral clearance capability is another critical component when developing a downstream process, as mammalian CHO-derived products have…